Harvest Integrated Research Organization (HiRO), a Shanghai-based Clinical Research Organization, has collaborated with CluePoints, to provide Risk-Based Quality Management (RBQM) expertise and technology in the Chinese region. This partnership will increase clinical trial efficiency and reduce deviation and bias to obtain accurate patient outcomes.
CluePoints' cloud-based products are deployed to support traditional on-site monitoring, medical review, and quality to drive an RBQM approach to study execution and ultimately achieve ICH E6 (R2) compliance.
The US Food and Drug Administration is also currently working with CluePoints as part of a cooperative research and development agreement (CRADA) to utilize CSM technology to inform the site inspection process and develop advanced statistical tests to identify moderators of treatment effect and analyze real-world evidence.
HiRO and CluePoints Partnership Offers RBQM Opportunities in China
Phase III Trial of Keytruda Plus Lynparza for NSCLC Stopped Due to Futility
December 7th 2023KEYLYNK-008 trial finds that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit in patients with metastatic squamous non-small cell lung cancer.
Key Phase III Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.